Spasmoplex
Spasmoplex - General Information
Spasmoplex is a urinary antispasmodic. It is sold under the brand name Sanctura in the US, and as Trosec in Canada. [Wikipedia]
Pharmacology of Spasmoplex
Spasmoplex is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Receptor assays showed that trospium has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses.
Spasmoplex for patients
Patients should be informed that anticholinergic agents, such as Sanctura, may produce clinically significant adverse effects related to anticholinergic pharmacological activity. For example, heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergics such as Sanctura are used in a hot environment. Because anticholinergics such as Sanctura may also produce dizziness or blurred vision, patients should be advised to exercise caution. Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents.
Sanctura should be taken 1 hour prior to meals or on an empty stomach. If a dose is skipped, patients are advised to take their next dose 1 hour prior to their next meal.
Spasmoplex Interactions
The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway. Careful patient monitoring is recommended in patients receiving such drugs.
Drug-Laboratory-Test Interactions
Interactions between Sanctura and laboratory tests have not been studied.
Spasmoplex Contraindications
Sanctura is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. Sanctura is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.
Additional information about Spasmoplex
Spasmoplex Indication: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
Mechanism Of Action: Spasmoplex antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Trospium
Synonyms: Trospium
Drug Category: Analgesics; Parasympatholytics
Drug Type: Small Molecule; Approved
Other Brand Names containing Trospium: Sanctura; Spasmex; Spasmoplex; Trosec;
Absorption: 9.6%
Toxicity (Overdose): Not Available
Protein Binding: 50-85%
Biotransformation: Not fully defined
Half Life: 20 hours
Dosage Forms of Spasmoplex: Tablet Oral
Chemical IUPAC Name: spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-di(phenyl)acetate
Chemical Formula: C25H30NO3+
Trospium on Wikipedia: https://en.wikipedia.org/wiki/Trospium
Organisms Affected: Humans and other mammals
